Cyberonics NCP Patient Adverse Events To Be Reviewed In Meeting With FDA
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics plans to meet with FDA to review adverse event data for certain patients who received its implantable NCP NeuroCybernetic Prosthesis vagus nerve stimulation system for epilepsy, including 83 deaths and 116 infections reported to the agency.
You may also be interested in...
Cyberonics Hits A Nerve: FDA Issues Firm Warning Letter For QSR Deficiencies
FDA's warning letter citing Cyberonics for quality system regulation lapses presents a further challenge for the device company as it seeks approval for a depression indication
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.